A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children

IF 6.5 1区 医学 Q1 ONCOLOGY International Journal of Radiation Oncology Biology Physics Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI:10.1016/j.ijrobp.2024.11.049
S. McGovern , J. Johnson , D. Luo , K. Nguyen , M. McAleer , A. Paulino , D. Grosshans , P. Baxter , W. Zaky , P. Thall , A. Mahajan
{"title":"A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children","authors":"S. McGovern ,&nbsp;J. Johnson ,&nbsp;D. Luo ,&nbsp;K. Nguyen ,&nbsp;M. McAleer ,&nbsp;A. Paulino ,&nbsp;D. Grosshans ,&nbsp;P. Baxter ,&nbsp;W. Zaky ,&nbsp;P. Thall ,&nbsp;A. Mahajan","doi":"10.1016/j.ijrobp.2024.11.049","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Reirradiation is increasingly considered for recurrent pediatric brain tumors, but dosimetric guidelines are lacking. To identify composite dose-volume constraints for reirradiation of recurrent brain tumors in children, a prospective trial was conducted.</div></div><div><h3>Methods</h3><div>Nine children with recurrent brain tumors previously treated with radiation were prospectively reirradiated. Three had GBM, two had AT/RT, and one each had ependymoma, NGGCT, medulloblastoma, or meningioma. For all patients, DICOM format records of their prior radiation (RT1) fields were obtained and deformed onto the CT simulation for their second course of radiation (RT2). Conventionally fractionated treatment plans for RT2 satisfied dose constraints for RT2 alone and the composite sum of both courses (RT1+RT2). The primary endpoint was the rate of symptomatic brain necrosis at 6 months after RT2.</div></div><div><h3>Results</h3><div>Median age at RT2 was 9.7y (range, 2.9 -6.8 y). Median interval between RT1 and RT2 was 19 months (range, 7–82 months). Treatment modality for RT2 was VMAT for seven patients and proton therapy for two patients. Median prescription dose for RT2 was 45 Gy (range, 30.6-60 Gy). Five patients were evaluable for the primary endpoint; none had symptomatic brain necrosis at 6 months after RT2. Four patients were not evaluble at 6 months due to death (n=2) or transition to hospice (n=2) by 6 months, all due to progression of disease. Median overall survival from RT2 start for all patients was 10.7 months (range, 5.2-46.4 months).</div></div><div><h3>Conclusions</h3><div>This prospective study suggests that conventionally fractionated reirradiation for recurrent brain tumors in children may be performed safely. These results provide a starting point for development of dose-volume constraints for pediatric brain reirradiation. Advanced technologies such as proton therapy may allow for reirradiation dose escalation while minimizing dose to surrounding critical structures.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Pages e13-e14"},"PeriodicalIF":6.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S036030162403623X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Reirradiation is increasingly considered for recurrent pediatric brain tumors, but dosimetric guidelines are lacking. To identify composite dose-volume constraints for reirradiation of recurrent brain tumors in children, a prospective trial was conducted.

Methods

Nine children with recurrent brain tumors previously treated with radiation were prospectively reirradiated. Three had GBM, two had AT/RT, and one each had ependymoma, NGGCT, medulloblastoma, or meningioma. For all patients, DICOM format records of their prior radiation (RT1) fields were obtained and deformed onto the CT simulation for their second course of radiation (RT2). Conventionally fractionated treatment plans for RT2 satisfied dose constraints for RT2 alone and the composite sum of both courses (RT1+RT2). The primary endpoint was the rate of symptomatic brain necrosis at 6 months after RT2.

Results

Median age at RT2 was 9.7y (range, 2.9 -6.8 y). Median interval between RT1 and RT2 was 19 months (range, 7–82 months). Treatment modality for RT2 was VMAT for seven patients and proton therapy for two patients. Median prescription dose for RT2 was 45 Gy (range, 30.6-60 Gy). Five patients were evaluable for the primary endpoint; none had symptomatic brain necrosis at 6 months after RT2. Four patients were not evaluble at 6 months due to death (n=2) or transition to hospice (n=2) by 6 months, all due to progression of disease. Median overall survival from RT2 start for all patients was 10.7 months (range, 5.2-46.4 months).

Conclusions

This prospective study suggests that conventionally fractionated reirradiation for recurrent brain tumors in children may be performed safely. These results provide a starting point for development of dose-volume constraints for pediatric brain reirradiation. Advanced technologies such as proton therapy may allow for reirradiation dose escalation while minimizing dose to surrounding critical structures.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿童原发性脑肿瘤再照射常规分级剂量限制的前瞻性研究
目的越来越多的儿童复发性脑肿瘤采用放射治疗,但缺乏剂量学指南。为了确定儿童复发性脑肿瘤再照射的复合剂量-体积限制,进行了一项前瞻性试验。方法对9例既往放射治疗的复发性脑肿瘤患儿进行前瞻性再放射治疗。3人患有GBM, 2人患有AT/RT, 1人患有室管膜瘤、NGGCT、成神经管细胞瘤或脑膜瘤。对于所有患者,获得其先前放射(RT1)场的DICOM格式记录,并将其变形到第二疗程放射(RT2)的CT模拟上。常规分级RT2治疗方案满足单独RT2和两个疗程(RT1+RT2)的剂量限制。主要终点是RT2后6个月症状性脑坏死的发生率。结果RT2时中位年龄为9.7岁(范围,2.9 -6.8岁),RT1与RT2间位间隔为19个月(范围,7-82个月)。RT2的治疗方式为VMAT治疗7例,质子治疗2例。RT2的处方中位剂量为45 Gy(范围30.6-60 Gy)。5例患者的主要终点可评估;RT2后6个月无症状性脑坏死。4名患者在6个月时因死亡(n=2)或6个月时过渡到安宁疗护(n=2)而无法评估,均因疾病进展。所有患者从RT2开始的中位总生存期为10.7个月(范围为5.2-46.4个月)。结论本前瞻性研究提示,对儿童复发性脑肿瘤进行常规分次再照射是安全的。这些结果为儿童脑再照射剂量-体积限制的发展提供了一个起点。先进的技术,如质子治疗,可能允许再照射剂量增加,同时尽量减少对周围关键结构的剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
Is deep learning ready for abdominal organ-at-risk segmentation in the foundation model era: A comprehensive study of challenging clinical cases. Split-Dose FLASH irradiation to investigate the clinical feasibility of multifield treatments. High-quality Four-dimensional Magnetic Resonance Fingerprinting (HQ-4DMRF) Reconstruction for Liver Cancer Radiotherapy. Patterns of failure after definitive ablative 5-fraction stereotactic body radiation therapy for inoperable pancreatic ductal adenocarcinoma. A learning-driven automatic planning framework for proton PBS treatments of H&N cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1